April 28 (Reuters) – An imminent ruling on Acadia
Pharmaceuticals Inc’s drug for Parkinson’s disease
psychosis is being closely watched by a Bermuda-based company
with a similar treatment for…
The post Acadia drug approval could clear way for Axovant dementia therapy appeared first on NASDAQ.